Media

May 23, 2018

A new milestone in the collaboration between RTM and Quirem Medical

As of the 22nd of May 2018, the Radboud Translational Medicine (RTM) is fully operational for performing the final steps in the manufacturing process of QuiremSpheres®. The RTM offers state-of-the-art facilities for the production and processing of radioactive pharmaceuticals and medical devices. Jan Sigger, CEO of Quirem Medical, comments: “It is rewarding to see that the intense collaboration of the team of RTM and our own team over the last months have now led to a seamless introduction of RTM as QuiremSpheres® manufacturing site. Through this collaboration we have been able to scale up our manufacturing capacity to meet the anticipated strong increase in demand for our products in the coming years.”